-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medicines are special commodities and are closely related to human health and safety
.
Therefore, in order to ensure the safety of people's medication, the state's supervision of pharmaceutical companies has been continuously increasing
.
It is worth noting that, in the context of the current accelerated reform and upgrading of the pharmaceutical system and the fact that on-site inspections have become the new normal of drug supervision, sampling inspections for the pharmaceutical industry in many provinces and cities have obviously begun to become more frequent
.
Recently, many places have successively released a series of random inspection results, among which a large number of pharmaceutical companies have been ordered to rectify and fined
.
On December 20, the Fujian Provincial Food and Drug Administration issued a notice on the results of random inspections of drug quality
.
During the random inspection, 8 batches of drugs that did not meet the requirements were found, including 3 Chinese herbal medicine pieces, 2 Chinese patent medicines, and 3 Western medicines
.
Involving enterprises including Shanxi, Tianjin Hui Xing Pharmaceutical Co.
, Ltd.
, Anhui King Road Biotech Co.
, Ltd.
, Anhui Diet Tong Chinese Herbal Medicine Co.
, Ltd.
, Jiangxi Far East Pharmaceutical Co.
, Ltd.
, Jiangxi Camphor Tian Qi Tong Chinese Herbal Medicine Co.
, Ltd.
and so on
.
It should be noted that, according to the review, two of the pharmaceutical companies investigated this time are "old faces" on the list of substandard drugs
.
Among them, Jiangxi Zhangshu Tianqitang Chinese Medicine Decoction Pieces Co.
, Ltd.
was ordered to make corrections, warned, and fined by the Jiangxi Provincial Food and Drug Administration only in June this year for producing and selling inferior medicines
.
In addition, Zhengzhou Zhuofeng Pharmaceutical Co.
, Ltd.
also had multiple batches of drugs that were found to be unqualified
.
Data shows that the pharmaceutical company has 14 records of drug substandards since 2018
.
At present, for the above-mentioned drugs and related enterprises (units) whose random inspection results do not meet the requirements, the Fujian Provincial Food and Drug Administration has required drug regulatory authorities at all levels to organize inspections and disposals in accordance with the law, and file cases for suspected illegal enterprises in accordance with the law
.
On December 17, the Guangxi Food and Drug Administration issued two administrative penalty announcements, penalizing Guangxi Lanzheng Pharmaceutical Co.
, Ltd.
and Guangxi Yulin Tailong Chinese Medicine Decoction Pieces Co.
, Ltd.
for the production and sales of inferior medicines.
.
Among them, Guangxi Lanzheng Pharmaceutical Co.
, Ltd.
was ordered to correct and confiscate the inferior drug Bupleurum and its illegal income, and fined one hundred and ten thousand yuan (￥160,000
.
Guangxi Yulin Tailong Chinese Medicine Decoction Pieces Co.
, Ltd.
was ordered to correct and confiscate the inferior drug Bupleurum and its illegal income, and was fined two hundred thousand yuan (￥200000.
00)
.
On December 1, Guizhou Bailing Group issued an announcement stating that the company's holding subsidiary He Rentang Pharmaceuticals had recently received the "Administrative Penalty Decision of Guiyang Market Supervision Administration
.
" For "not strictly implementing the registered process to produce" Kangfuling Capsules, Rentang Pharmaceutical was fined RMB 32,068,379.
63 by the Guiyang Market Supervision Bureau, and 238,922 boxes of the drug "Kangfuling Capsules" that were illegally produced and recalled after sales were confiscated
.
On the whole, since 2021, news about drug companies taking fines has actually been circulating continuously.
The reasons can be described as various, including violations of laws and regulations in the production process, touching the anti-monopoly "red line", and selling inferior drugs
.
In this context, the industry generally believes that in the future, pharmaceutical companies will regulate their operations, adjust their production and operation strategies in a timely manner, and continuously improve product quality, which is the real way to survive
.
.
Therefore, in order to ensure the safety of people's medication, the state's supervision of pharmaceutical companies has been continuously increasing
.
It is worth noting that, in the context of the current accelerated reform and upgrading of the pharmaceutical system and the fact that on-site inspections have become the new normal of drug supervision, sampling inspections for the pharmaceutical industry in many provinces and cities have obviously begun to become more frequent
.
Recently, many places have successively released a series of random inspection results, among which a large number of pharmaceutical companies have been ordered to rectify and fined
.
On December 20, the Fujian Provincial Food and Drug Administration issued a notice on the results of random inspections of drug quality
.
During the random inspection, 8 batches of drugs that did not meet the requirements were found, including 3 Chinese herbal medicine pieces, 2 Chinese patent medicines, and 3 Western medicines
.
Involving enterprises including Shanxi, Tianjin Hui Xing Pharmaceutical Co.
, Ltd.
, Anhui King Road Biotech Co.
, Ltd.
, Anhui Diet Tong Chinese Herbal Medicine Co.
, Ltd.
, Jiangxi Far East Pharmaceutical Co.
, Ltd.
, Jiangxi Camphor Tian Qi Tong Chinese Herbal Medicine Co.
, Ltd.
and so on
.
It should be noted that, according to the review, two of the pharmaceutical companies investigated this time are "old faces" on the list of substandard drugs
.
Among them, Jiangxi Zhangshu Tianqitang Chinese Medicine Decoction Pieces Co.
, Ltd.
was ordered to make corrections, warned, and fined by the Jiangxi Provincial Food and Drug Administration only in June this year for producing and selling inferior medicines
.
In addition, Zhengzhou Zhuofeng Pharmaceutical Co.
, Ltd.
also had multiple batches of drugs that were found to be unqualified
.
Data shows that the pharmaceutical company has 14 records of drug substandards since 2018
.
At present, for the above-mentioned drugs and related enterprises (units) whose random inspection results do not meet the requirements, the Fujian Provincial Food and Drug Administration has required drug regulatory authorities at all levels to organize inspections and disposals in accordance with the law, and file cases for suspected illegal enterprises in accordance with the law
.
On December 17, the Guangxi Food and Drug Administration issued two administrative penalty announcements, penalizing Guangxi Lanzheng Pharmaceutical Co.
, Ltd.
and Guangxi Yulin Tailong Chinese Medicine Decoction Pieces Co.
, Ltd.
for the production and sales of inferior medicines.
.
Among them, Guangxi Lanzheng Pharmaceutical Co.
, Ltd.
was ordered to correct and confiscate the inferior drug Bupleurum and its illegal income, and fined one hundred and ten thousand yuan (￥160,000
.
Guangxi Yulin Tailong Chinese Medicine Decoction Pieces Co.
, Ltd.
was ordered to correct and confiscate the inferior drug Bupleurum and its illegal income, and was fined two hundred thousand yuan (￥200000.
00)
.
On December 1, Guizhou Bailing Group issued an announcement stating that the company's holding subsidiary He Rentang Pharmaceuticals had recently received the "Administrative Penalty Decision of Guiyang Market Supervision Administration
.
" For "not strictly implementing the registered process to produce" Kangfuling Capsules, Rentang Pharmaceutical was fined RMB 32,068,379.
63 by the Guiyang Market Supervision Bureau, and 238,922 boxes of the drug "Kangfuling Capsules" that were illegally produced and recalled after sales were confiscated
.
On the whole, since 2021, news about drug companies taking fines has actually been circulating continuously.
The reasons can be described as various, including violations of laws and regulations in the production process, touching the anti-monopoly "red line", and selling inferior drugs
.
In this context, the industry generally believes that in the future, pharmaceutical companies will regulate their operations, adjust their production and operation strategies in a timely manner, and continuously improve product quality, which is the real way to survive
.
